As innovation accelerates, life sciences companies must align patent strategy with long-term growth. This update explores how portfolio design, operational structure, and early IP decisions shape flexibility, commercialization, and long-term value.

Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.

Patents may last 20 years on paper, but real market protection for a drug or biologic depends on how you combine patent terms, extensions, and US/EU regulatory exclusivity. This article explains the key building blocks in plain language for life sciences teams.

In life sciences and advanced materials sector, IP due diligence is more than a legal formality; it’s central to valuation, deal viability, and long-term competitiveness. This article outlines a practical roadmap for investors and growth-stage companies to assess IP assets, FTO, risk, and strategy with the rigor these transactions demand.

Intellectual property is the foundation of biotech success. Discover how platform-driven IP strategies, licensing frameworks, and strategic collaborations can amplify valuation, attract investors, and accelerate commercialization. Learn how Hylton Rodic Law helps biotech innovators protect the science, structure the deal, and scale the business.

We’ve just returned from the Life Sciences Strategy Summit in Munich, where Keisha Hylton-Rodic joined global experts to explore divisional patenting and the evolving IP landscape. The conversations were rich, the insights actionable, and the collaboration inspiring.